Edition:
United States

Intercept Pharmaceuticals Inc (ICPT.OQ)

ICPT.OQ on NASDAQ Stock Exchange Global Select Market

92.00USD
4:00pm EDT
Change (% chg)

$-3.72 (-3.89%)
Prev Close
$95.72
Open
$96.59
Day's High
$96.82
Day's Low
$89.85
Volume
223,731
Avg. Vol
199,741
52-wk High
$133.71
52-wk Low
$51.11

Chart for

About

Intercept Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company's product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic... (more)

Overall

Beta: -1.63
Market Cap(Mil.): $3,195.65
Shares Outstanding(Mil.): 29.56
Dividend: --
Yield (%): --

Financials

  ICPT.OQ Industry Sector
P/E (TTM): -- 119.85 32.14
EPS (TTM): -13.11 -- --
ROI: -65.24 1.96 12.83
ROE: -215.41 1.12 14.95

BRIEF-Intercept Pharmaceuticals Says 2018 Worldwide Ocaliva Net Sales Currently Expected To Be Between $170 Mln-$185 Mln

* INTERCEPT PHARMACEUTICALS ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS, ISSUES 2018 OCALIVA NET SALES GUIDANCE AND PROVIDES BUSINESS UPDATE

May 08 2018

BRIEF-Intercept Pharmaceuticals CEO Mark Pruzanski's FY 2017 Total Compensation Was $6.2 Million

* INTERCEPT PHARMACEUTICALS SAYS CEO MARK PRUZANSKI'S FY 2017 TOTAL COMPENSATION WAS $6.2 MILLION VERSUS $4.8 MILLION IN 2016 - SEC FILING Source text for Eikon: (http://bit.ly/2KlDqOX) Further company coverage:

Apr 27 2018

BRIEF-Intercept Pharmaceuticals Says Co's Board Increased Size Of Board From Nine Directors To Ten Directors

* INTERCEPT PHARMACEUTICALS SAYS EFFECTIVE APRIL 24, CO'S BOARD INCREASED SIZE OF BOARD FROM NINE DIRECTORS TO TEN DIRECTORS - SEC FILING Source text: [https://bit.ly/2JsU4uo] Further company coverage:

Apr 27 2018

Earnings vs. Estimates